Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Trends in intensity-modulated radiation therapy use for rectal cancer in the neoadjuvant setting: a National Cancer Database analysis

  • Wegner, Rodney E. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Abel, Stephen (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • White, Richard J. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Horne, Zachary D. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Hasan, Shaakir (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Kirichenko, Alexander V. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute)
  • Received : 2018.10.18
  • Accepted : 2018.11.01
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Traditionally, three-dimensional conformal radiation therapy (3D-CRT) is used for neoadjuvant chemoradiation in locally advanced rectal cancer. Intensity-modulated radiation therapy (IMRT) was later developed for more conformal dose distribution, with the potential for reduced toxicity across many disease sites. We sought to use the National Cancer Database (NCDB) to examine trends and predictors for IMRT use in rectal cancer. Materials and Methods: We queried the NCDB from 2004 to 2015 for patients with rectal adenocarcinoma treated with neoadjuvant concurrent chemoradiation to standard doses followed by surgical resection. Odds ratios were used to determine predictors of IMRT use. Univariable and multivariable Cox regressions were used to determine potential predictors of overall survival (OS). Propensity matching was used to account for any indication bias. Results: Among 21,490 eligible patients, 3,131 were treated with IMRT. IMRT use increased from 1% in 2004 to 22% in 2014. Predictors for IMRT use included increased N stage, higher comorbidity score, more recent year, treatment at an academic facility, increased income, and higher educational level. On propensity-adjusted, multivariable analysis, male gender, increased distance to facility, higher comorbidity score, IMRT technique, government insurance, African-American race, and non-metro location were predictive of worse OS. Of note, the complete response rate at time of surgery was 28% with non-IMRT and 21% with IMRT. Conclusion: IMRT use has steadily increased in the treatment of rectal cancer, but still remains only a fraction of overall treatment technique, more often reserved for higher disease burden.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7-30.
  2. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
  3. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926-33.
  4. Sineshaw HM, Jemal A, Thomas CR Jr, Mitin T. Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: an analysis from the National Cancer Data Base. Cancer 2016;122:1996-2003.
  5. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880-914.
  6. Fredman ET, Abdel-Wahab M, Kumar AMS. Influence of radiation treatment technique on outcome and toxicity in anal cancer. J Radiat Oncol 2017;6:413-21.
  7. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27-33.
  8. Taylor N, Crane C, Skibber J, et al. Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. Int J Radiat Oncol Biol Phys 2001;51:741-7.
  9. Patel S, Vuong T, Ballivy O, Portelance L, Parker W, Patrocinio H. Phase II trial of pelvic intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy for patients with rectal cancer. Int J Radiat Oncol Biol Phys 2014;60:S424-S425.
  10. Mok H, Crane CH, Palmer MB, et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 2011;6:63.
  11. Parekh A, Truong MT, Pashtan I, et al. Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointest Cancer Res 2013;6:137-43.
  12. Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis. Lung Cancer 2018;124:283-90.
  13. Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) Analysis. Ann Surg 2018 Sep 13 [Epub]. http://doi.org/10.1097/SLA.0000000000003051.
  14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
  15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
  16. Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol 1972;34:187-220.
  17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
  18. Olsen JR, Moughan J, Myerson R, et al. Predictors of radiation therapy-related gastrointestinal toxicity from anal cancer dose-painted intensity modulated radiation therapy: secondary analysis of NRG Oncology RTOG 0529. Int J Radiat Oncol Biol Phys 2017;98:400-8.
  19. Haque W, Verma V, Butler EB, Teh BS. Utilization of intensity modulated radiation therapy for anal cancer in the United States. J Gastrointest Oncol 2018;9:466-77.
  20. Reyngold M, Niland J, Ter Veer A, et al. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. Adv Radiat Oncol 2017;3:34-41.
  21. Sun Z, Adam MA, Kim J, Czito B, Mantyh C, Migaly J. Intensity-modulated radiation therapy is not associated with perioperative or survival benefit over 3D-conformal radiotherapy for rectal cancer. J Gastrointest Surg 2017;21:106-11.

Cited by

  1. Practice patterns and outcomes following radiation dose de‐escalation for oropharyngeal cancer vol.130, pp.4, 2018, https://doi.org/10.1002/lary.28083
  2. DUOX2, a New Biomarker for Disseminated Gastric Cancer’s Response to Low Dose Radiation in Mice vol.13, pp.16, 2018, https://doi.org/10.3390/cancers13164186
  3. Radiation Oncology Alternative Payment Model and Large Urban Academic Centers: Future Implications for Patients and Providers vol.17, pp.12, 2018, https://doi.org/10.1200/op.21.00347